Publications by authors named "J Ciolkowski"
Article Synopsis
- The study aimed to evaluate how effective a hypertonic saline test for indirect airway hyperresponsiveness (AHR) is in managing inhaled corticosteroids (ICS) for controlling asthma in children aged 7-15 with mild to moderate atopic asthma.
- A total of 104 patients were divided into two groups: one was monitored for symptoms only, while the other had their therapy adjusted based on AHR severity, using various assessments every three months for a year.
- Results showed that the AHR group experienced fewer mild asthma exacerbations compared to the symptom-only group, although final ICS doses were similar, indicating the hypertonic saline test may be a useful, low-cost method for monitoring asthma in pediatric patients.*
Background: Stability of asthma is a clinical phenotype of the disease based on long-term evaluation of control of asthma symptoms and its exacerbations. A relationship between airway inflammation and clinical classification of asthma based on stability criterion has not been well studied.
Objectives: The purpose of our study was to analyze the inflammation profile of stable and unstable asthma in adolescents treated with moderate and high doses of inhaled corticosteroids.
Introduction: Asthma control is an important measure of disease stabilization, which is linked to the treatment and lifestyle recommendations.
Aim: To assess the impact of selected factors on asthma control in adolescents, as assessed using the Asthma Control Test (ACT™).
Material And Methods: The prospective study included 100 asthma patients aged between 12 and 19.
Background: Asthma guidelines allow anti-leukotriene medications to be used as an alternative to inhaled corticosteroids (ICS) in second-step intensity therapy. The aim of the study was to analyze the risk factors of exacerbations, particularly inflammatory markers, during the 12-month period following therapy reduction from an ICS to montelukast in young patients with mild asthma.
Methods: A total of 84 patients (aged 7-18 years old) with mild asthma controlled by low-dose ICS, had their treatment switched to montelukast.